MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a "neutral" rating and a price target of $65.00, indicating an upside potential of 18.03% from its last closing price.
• Other analysts, including Wedbush and Royal Bank of Canada, have issued "outperform" ratings with price targets ranging from $61.00 to $80.00, contributing to a consensus rating of "Moderate Buy" and an average target of $73.14.
• MoonLake reported a quarterly loss of ($0.63) EPS, which beat analysts' expectations, and has a market capitalization of $3.53 billion with significant institutional ownership of 93.85%.

Investment analysts at Rothschild & Co Redburn started coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) in a research note issued on Monday,Briefing.com Automated Import reports. The brokerage set a "neutral" rating and a $65.00 price target on the stock. Rothschild & Co Redburn's price target indicates a potential upside of 18.03% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. Wedbush reaffirmed an "outperform" rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Wolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a report on Monday, May 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $73.14.

MoonLake Immunotherapeutics Stock Up 0.1%

Shares of MLTX opened at $55.07 on Monday. The firm has a 50 day simple moving average of $46.16 and a two-hundred day simple moving average of $42.60. The company has a market cap of $3.53 billion, a P/E ratio of -23.94 and a beta of 1.27. The company has a debt-to-equity ratio of 0.18, a current ratio of 21.11 and a quick ratio of 21.11. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same quarter in the previous year, the business posted ($0.22) earnings per share. Research analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently added to or reduced their stakes in MLTX. Teacher Retirement System of Texas boosted its position in MoonLake Immunotherapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock valued at $354,000 after purchasing an additional 1,013 shares in the last quarter. Sei Investments Co. boosted its stake in MoonLake Immunotherapeutics by 5.8% in the 4th quarter. Sei Investments Co. now owns 22,025 shares of the company's stock worth $1,193,000 after purchasing an additional 1,202 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in MoonLake Immunotherapeutics in the 4th quarter worth approximately $244,000. LPL Financial LLC boosted its stake in MoonLake Immunotherapeutics by 19.5% in the 4th quarter. LPL Financial LLC now owns 8,146 shares of the company's stock worth $441,000 after purchasing an additional 1,332 shares in the last quarter. Finally, DnB Asset Management AS boosted its stake in MoonLake Immunotherapeutics by 11.3% in the 4th quarter. DnB Asset Management AS now owns 8,356 shares of the company's stock worth $452,000 after purchasing an additional 847 shares in the last quarter. Institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.